Hypothalamic obesity is severe, rapid, and largely uncontrolled weight gain caused by damage or dysfunction in the hypothalamic regions that regulate hunger and energy balance, particularly the MC4R signaling pathway. The condition takes two forms. Acquired hypothalamic obesity follows surgery, radiation, or trauma involving the hypothalamus, most commonly after craniopharyngioma resection in children. Genetic hypothalamic obesity arises from monogenic defects in POMC, PCSK1, LEPR, or MC4R itself.
In either form, patients gain weight at rates that exceed normal physiology, do not respond to diet or exercise, and historically had no targeted treatment options. Bariatric surgery has poor outcomes in this population; conventional appetite suppressants are mostly ineffective.
The field changed in 2020 when the FDA approved Rhythm Pharmaceuticals' setmelanotide (IMCIVREE) for POMC, PCSK1, and LEPR deficiency obesity. The label expanded to Bardet-Biedl Syndrome in 2022 and acquired hypothalamic obesity in March 2026 after the Phase 3 TRANSCEND trial showed 18.4% placebo-adjusted BMI reduction at 52 weeks. A 2.5-year long-term extension presented at ENDO 2026 (Christian Roth, Seattle Children's) reported -18.9% mean BMI reduction across all 11 participants, with sustained efficacy. Rhythm's next-generation MC4R agonist bivamelagon is now advancing.
Stories here cover hypothalamic obesity trial readouts, real-world data, and the targeted-therapy pipeline. See [[setmelanotide]], [[mc4r]], and [[rhythm-pharmaceuticals]] for adjacent threads.
Rhythm Pharmaceuticals (NASDAQ: RYTM) reported on the August 4, 2026 Q2 2026 earnings call that the US launch of IMCIVREE (setmelanotide) in the newly-approved acquired hypothalamic obesity indication has recorded more than 400 patient start forms since FDA approval in late June 2026. Setmelanotide is a synthetic alpha-melanocyte-stimulating hormone (alpha-MSH) analog peptide that activates the melanocortin-4 receptor (MC4R) to produce appetite suppression; the peptide is administered as a daily subcutaneous injection. The launch ranks among the stronger rare-disease peptide launches of the year to date and extends the melanocortin-agonist franchise beyond the original rare genetic obesity syndromes (POMC, LEPR, PCSK1 deficiency) that IMCIVREE was initially approved for in 2020. The acquired hypothalamic obesity indication addresses patients with hypothalamic damage from brain tumors (particularly craniopharyngioma), radiation therapy, surgery, or trauma that disrupts normal melanocortin signaling and leads to severe obesity with dysfunctional appetite regulation. The therapeutic story is mechanistically adjacent to but distinct from the alpha-MSH gray-market use of melanotan II (which activates the same broader melanocortin receptor family for tanning and appetite suppression); setmelanotide has substantially more selectivity for MC4R specifically, an established safety monitoring program, and full FDA approval under the rare-disease pathway. IMCIVREE full-year 2026 revenue guidance is expected to reflect the acquired hypothalamic obesity launch trajectory.
Rhythm Pharmaceuticals (Nasdaq: RYTM) presented seven setmelanotide abstracts at ENDO 2026 covering three rare-disease patient populations. Christian Roth (Seattle Children's) reported 2.5-year Phase 2 + long-term extension data in acquired hypothalamic obesity showing -18.9% mean BMI reduction across all 11 participants. The PWS interim Phase 2 (June 13) reported across 17 patients (10 adult, 7 pediatric) showed 3.11% mean BMI reduction in adults and 3.00% in pediatric patients, with 8 of 10 baseline-hyperphagic patients hitting a 7-point HQ-CT reduction, and 4.19% fat-mass loss with 0.74% lean-mass gain across 16 DEXA evaluations. Two BBS late-breaking posters from Caroline Huber covered real-world hyperphagia and healthcare-utilization outcomes from the 6-month RESTORE study. All three indications reinforce the MC4R-agonist rationale for Phase 3.
Rhythm Pharmaceuticals reported Q1 2026 results May 5: setmelanotide (IMCIVREE) net product revenue of $60.1M, up from $37.7M a year earlier ($36.9M US, $23.2M ex-US), driven by 150+ new US start forms in acquired hypothalamic obesity following the FDA approval and the EU Marketing Authorization for the same indication; Japan's PMDA accepted the NDA for review. The MC4R-agonist peptide is the only commercial therapy for hypothalamic obesity. Offsetting the topline beat: the Phase 3 EMANATE trial in genetically caused MC4R-pathway diseases failed its primary endpoint in all four independent substudies, narrowing the indication-expansion runway. Net loss was $56.7M; cash $340.6M for 24+ months runway.
FDA approved setmelanotide (IMCIVREE), an MC4R agonist peptide, for reducing body weight in adults and children aged 4+. Phase 3 TRANSCEND trial showed 18.4% placebo-adjusted BMI reduction at 52 weeks.